PORTLAND, Ore., November 26, 2019 – Nobilis Therapeutics announced today the issuance of the patent (U.S. Patent No: 10,485,825 ) titled “Prevention of Pregnancy Complications by Noble Gas Administration.”
“The impetus to filing this patent stems from the recognized anti-inflammatory and immunomodulatory effects of our drug,” said Vlad Bogin, CEO of Nobilis Therapeutics. “As one of the causes of Recurrent Spountaneus Abortions has been ascribed to the exaggerated maternal anti-fetal response, utilizing the properties of our nontoxic and metabolically inert therapeutic could be of significant benefit. Clearly, this concept will require further investigations,” continued Dr. Bogin.
About Nobilis Therapeutics
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric, neurodegenerative and other diseases and leverages the experience of its international team that has studied this technology in the treatment of over 2000 patients for conditions ranging from panic attacks to substance abuse. The Company has filed an IND to initiate a phase IIb/III clinical trial to evaluate the efficacy of NBTX-001, its lead compound, for the treatment of patients with PTSD.